Merck & Co. 10-Qquarter ended 2026-09-30

Executive Summary

Merck earns revenue from medicines and vaccines for patients and health systems, and animal-health products for livestock producers and pet owners. It is expanding beyond intravenous Keytruda through subcutaneous Keytruda Qlex, newer medicines and acquisitions of influenza-prevention and cancer candidates. Q3 sales rose 4.7%, but purchase timing helped materially, while acquisition-related costs and spending on future products weighed on earnings. For investors, the opportunity is a broader growth portfolio; the challenge is replacing medicines losing exclusivity while protecting Keytruda’s commercial reach and pricing.

What's Happening in the Business

Keytruda Qlex is changing the delivery of Merck’s largest franchise. Its quarterly sales reached $830M as intravenous Keytruda sales declined, leaving combined franchise sales higher. Merck continued expanding approved uses, but European injunctions restrict Qlex commercialization. Management expects Keytruda inventory to unwind in Q4, making underlying demand more important than shipments.

Winrevair’s expansion and Ohtuvayre, acquired with Verona Pharma, are adding growth outside oncology. Meanwhile, generic competition is eroding established medicines: Januvia and Janumet lost U.S. exclusivity during 2026, followed by Bridion in July. Merck expects continued significant U.S. declines for Januvia and Janumet.

Gardasil’s quarterly recovery does not yet establish a sustained turnaround. U.S. pricing and public-sector purchases helped, but weakness in China and Japan left nine-month sales nearly flat. Limited China shipments resumed after the earlier suspension; management expects immaterial revenue under the revised contract in 2026 and the U.S. purchasing benefit to unwind in 2027.

Merck is buying future products as older franchises weaken. Cidara cost $9.2B, principally adding a Phase 3 influenza-prevention candidate; Terns cost $6.8B, principally adding a clinical-stage leukemia candidate. Neither is yet a commercial replacement. Pipeline progress was mixed: sacituzumab tirumotecan received priority review, while Merck withdrew ifinatamab deruxtecan’s U.S. accelerated-approval application after FDA discussions; its Phase 3 trial continues.

Key Financial Highlights

• Keytruda franchise: Combined Keytruda/Qlex sales reached $8.60B, +5.6%; intravenous Keytruda alone fell 4.6%, versus 1.2% growth over nine months. The formulation shift matters when assessing the franchise.
• Newer products: Winrevair contributed $694M, +93%, reflecting demand, launches and purchase timing expected to reverse in Q4; Ohtuvayre added $184M.
• Animal Health: Poultry and ruminant demand and companion-animal launches supported growth, partly offset by lower vaccine pricing and weaker demand for some products.
• Earnings burden: Nine-month acquired R&D charges totaled $14.7B. Q3 segment profits exclude substantial costs: unallocated R&D rose 14% to $4.37B, amortization rose 70% to $1.06B, and interest expense rose 67% to $546M.
• Cash and financing: Nine-month FCF was $12.9B, but acquisitions drove $17.1B of investing outflows. Total debt reached $53.8B, +9.0% from year-end, while cash, cash equivalents and restricted cash fell 34% to $9.65B.

Risk Assessment

• Franchise erosion and pricing: Generic competition is already shrinking established medicines, while German reimbursement pressure and expected U.S. negotiated pricing for Keytruda from 2029 threaten the largest franchise.
• Acquisition execution: Cidara and Terns require clinical and regulatory success; failure would leave Merck with acquisition spending and financing costs without replacement revenue.
• Commercialization and legal exposure: European Qlex injunctions could restrict adoption, while product-liability proceedings, government investigations and a disputed IRS transition-tax assessment could create additional cash costs.
• Financial flexibility: Acquisition-driven debt growth and lower cash increase the burden of funding development, shareholder distributions and future obligations.

No risk-factor section was found in this 10-Q. A 10-Q does not have to restate the risk factors in the annual report. Full list: FY2025 10-K.

What to Watch

• Keytruda/Qlex: Combined sales are growing despite intravenous declines; sustained franchise demand and broader Qlex access would support the transition, while inventory unwinding or injunctions could expose weaker growth.
• Replacement portfolio: Winrevair and Ohtuvayre are contributing revenue, while the acquired candidates remain in development; sustained commercial growth and successful trials would validate diversification, while setbacks would prolong Keytruda dependence.
• Gardasil: Nine-month sales are nearly flat; renewed end-market demand in China and Japan would support recovery, whereas continued weakness after purchasing benefits reverse would undermine it.
• Funding capacity: Later filings should show whether cash generation rebuilds liquidity and contains debt while development spending continues, or acquisitions and distributions require further borrowing.

Not present in this filing: Part II Item 1A, Risk Factors.